ENDRA Life Sciences's book value per share for the quarter that ended in Mar. 2024 was $0.00.
During the past 12 months, ENDRA Life Sciences's average Book Value Per Share Growth Rate was -76.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -49.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -46.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of ENDRA Life Sciences was 30.50% per year. The lowest was -49.40% per year. And the median was -37.60% per year.
During the past 10 years, the highest P/B Ratio of ENDRA Life Sciences was 6.69. The lowest was 0.01. And the median was 1.16.
ENDRA Life Sciences Book Value per Share Historical Data
The historical data trend for ENDRA Life Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ENDRA Life Sciences's Book Value per Share
For the Diagnostics & Research subindustry, ENDRA Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's PB Ratio falls into.
ENDRA Life Sciences Book Value per Share Calculation
ENDRA Life Sciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
ENDRA Life Sciences (NAS:NDRAU) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
ENDRA Life Sciences Book Value per Share Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRAU has been successfully added to your 